All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
FDA accepts New Drug Application and grants Priority Review status to glasdegib for the treatment of patients with previously untreated AML
On 27 June 2018, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted priority review to glasdegib, an oral smoothened (SMO) inhibitor, for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) in combination with low dose chemotherapy (LDAC).1
The NDA submission was based on data from the randomized, open-label, phase II BRIGHT 1003 study (NCT01546038), which is evaluating the safety and efficacy of glasdegib (PF-04449913) with (n = 88) or without (n = 44) LDAC in 132 patients with AML. The results of this study were presented at the 2016 American Society of Hematology (ASH) Annual Meeting by Jorge Cortes from The University Texas MD Anderson Cancer Center, Houston, TX, and reported by the AML Global Portal here. Results demonstrated a significant improvement in the primary endpoint of overall survival (OS). Median OS was 8.8 months for patients treated with glasdegib plus LDAC compared with 4.9 months for patients treated with LDAC only. This difference represented a 49.9% reduction in the risk of death for patients treated with glasdegib plus LDAC (HR = 0.501, 95% CI: 0.334–0.752, P = 0.0003). In summary, the addition of glasdegib to LDAC for AML and high-risk MDS patients improved OS compared with LDAC alone and this survival benefit was consistent among cytogenetic subgroups.2
At present, glasdegib is being assessed in a phase III BRIGHT AML1019 trial (NCT03416179), which is evaluating the addition of glasdegib to intensive or non-intensive chemotherapy in patients with newly diagnosed AML, began enrolling earlier this year. Jorge Cortes discusses the design of this phase III study here.
References